Showing results (391-400 of 405) with videos related to

Sort By:
Pageof 41
The Lancet. Infectious Diseases|January 31, 2026
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trialScott K Heysell, Stellah G Mpagama, Edwin Nuwagira, et al.
Open Forum Infectious Diseases|November 18, 2020
Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19Sarah M Lofgren, Melanie R Nicol, Ananta S Bangdiwala, et al.
The New England Journal of Medicine|March 30, 2022
Effect of Early Treatment with Ivermectin among Patients with Covid-19Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva, et al.
JAMA|November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical TrialThomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2022
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT TrialDavid R Boulware, Thomas A Murray, Jennifer L Proper, et al.
The Lancet. Infectious Diseases|June 11, 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trialCarolyn T Bramante, John B Buse, David M Liebovitz, et al.
The New England Journal of Medicine|September 7, 2022
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19Carolyn T Bramante, Jared D Huling, Christopher J Tignanelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2024
Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19Carolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, et al.
Pageof 41